<DOC>
	<DOCNO>NCT00006916</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining radiation therapy chemotherapy may kill tumor cell . PURPOSE : Phase II trial study effectiveness radiation therapy follow bleomycin treat adult patient newly diagnose supratentorial glioblastoma multiforme .</brief_summary>
	<brief_title>Radiation Therapy Followed Bleomycin Treating Adult Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme</brief_title>
	<detailed_description>OBJECTIVES : - Determine median survival time patient newly diagnose supratentorial glioblastoma multiforme treat radiotherapy follow sustained release intratumoral bleomycin . - Determine feasibility regimen patient . OUTLINE : This multicenter study . Within 4 week surgical resection , patient receive radiotherapy daily 5 day week 6 week . Within 2-6 week completion radiotherapy disease progression radiotherapy , patient undergo surgical implantation modify Ommaya reservoir within central area tumor . Patients receive sustain release bleomycin intratumorally via reservoir week 2 year absence disease progression unacceptable toxicity . Patients follow every 3 month 2 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 72 patient accrue study within 5 month .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm supratentorial glioblastoma multiforme ( area necrosis ) surgical biopsy excision within 4 week study Tumor and/or associate edema limited one hemisphere unifocal No gross invasion ventricular surface Tumor accessible No astrocytoma No multifocal recurrent malignant glioma No disease tentorium beyond cranial vault PATIENT CHARACTERISTICS : Age : Adult Performance status : Zubrod 01 Life expectancy : At least 8 week Hematopoietic : Hemoglobin least 10 g/dL ( transfusion allow ) Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 2.0 mg/dL Serum glutamicoxaloacetic transaminase ( SGOT ) Serum glutamicpyruvic transaminase ( SGPT ) great 2 time normal Renal : Blood Urea Nitrogen ( BUN ) great 25 mg/dL Creatinine great 1.5 mg/dL Other : Not pregnant nursing Fertile patient must use effective contraception No hypersensitive idiosyncratic reaction bleomycin No prior malignancy within past 2 year except nonmelanomatous skin cancer carcinoma situ cervix urinary bladder No major medical illness psychiatric impairment would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy glioblastoma multiforme No prior radiosensitizer glioblastoma multiforme Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy head neck result overlap radiotherapy field Surgery : See Disease Characteristics Recovered prior surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>